Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00242827 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma

A Phase 2 study, sponsored by Cephalon.

Terminated
Registry status
Phase 2
Development phase

NCT00242827: Clinical Trial Phase 2 study, sponsored by Cephalon.

NCT00242827 is a Phase 2 study that was terminated before completion, run by Cephalon. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00242827, a Phase 2 study, was terminated before completion, sponsored by Cephalon.

TERMINATED
Registry status
Phase 2
Development phase

Study Summary

An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients with Advanced Multiple Myeloma.

Interventions

  • DRUG Oral CEP-701

Trial Details

FieldValue
Start Date 2006-04
Est. Completion 2007-05
Phase Phase 2
Cephalon

64 total trials

Why NCT00242827 stopped before completion

NCT00242827 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which Oral CEP-701 is the first listed.

NCT00242827 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00242827 about?

NCT00242827 is a clinical study titled "Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma". An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients with Advanced Multiple Myeloma.

What is the current status of trial NCT00242827?

This trial is currently terminated. It is a Phase 2 study. The study started on 2006-04. Estimated completion is 2007-05.

What interventions are being tested in trial NCT00242827?

The interventions under investigation include: Oral CEP-701 (DRUG).

Who is sponsoring clinical trial NCT00242827?

This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00242827, the US trial registry maintained by the National Library of Medicine. NCT00242827 (unsized enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.